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ABSTRACT
Background Despite most cases not requiring hospital 
care, there are limited community- based clinical data on 
COVID-19.
Methods The Corona São Caetano programme is a 
primary care initiative providing care to all residents with 
COVID-19 in São Caetano do Sul, Brazil. It was designed to 
capture standardised clinical data on community COVID-19 
cases. After triage of potentially severe cases, consecutive 
patients presenting to a multimedia screening platform 
between 13 April and 13 May 2020 were tested at home 
with SARS- CoV-2 reverse transcriptase (RT) PCR; positive 
patients were followed up for 14 days with phone calls 
every 2 days. RT- PCR- negative patients were offered 
additional SARS- CoV-2 serology testing to establish their 
infection status. We describe the clinical, virological and 
natural history features of this prospective population- 
based cohort.
Findings Of 2073 suspected COVID-19 cases, 1583 
(76.4%) were tested by RT- PCR, of whom 444 (28.0%, 
95% CI 25.9 to 30.3) were positive; 604/1136 (53%) RT- 
PCR- negative patients underwent serology, of whom 52 
(8.6%) tested SARS- CoV-2 seropositive. The most common 
symptoms of confirmed COVID-19 were cough, fatigue, 
myalgia and headache; whereas self- reported fever (OR 
3.0, 95% CI 2.4 to 3.9), anosmia (OR 3.3, 95% CI 2.6 to 
4.4) and ageusia (OR 2.9, 95% CI 2.3 to 3.8) were most 
strongly associated with a positive COVID-19 diagnosis by 
RT- PCR or serology. RT- PCR cycle thresholds were lower 
in men, older patients, those with fever and arthralgia 
and closer to symptom onset. The rates of hospitalisation 
and death among 444 RT- PCR- positive cases were 6.7% 
and 0.7%, respectively, with older age and obesity more 
frequent in the hospitalised group.
Conclusion COVID-19 presents in a similar way to 
other mild community- acquired respiratory diseases, but 
the presence of fever, anosmia and ageusia can assist 
the specific diagnosis. Most patients recovered without 
requiring hospitalisation with a low fatality rate compared 
with other hospital- based studies.
INTRODUCTION
A comprehensive public health response 
is vital but difficult to achieve during an 
epidemic. The COVID-19 pandemic, caused 
by the novel SARS- CoV-2, started in China in 
late 2019.1 According to the World Health 
Organization (WHO)2 3 and others,4 5 the 
ideal early response should have been multi-
pronged, with identification, isolation, treat-
ment and contact tracing of symptomatic 
cases, relying on a strong testing programme. 
Primary healthcare (PHC) is well placed to 
implement such a response, by identifying 
cases early and managing them in a way that 
minimises overcrowding of emergency rooms 
and intensive care units.6 7 Real- time data 
Strengths and limitations of this study
 ► The clinical features of COVID-19 have mostly been 
described in hospital- based studies which are bi-
assed towards severe disease.
 ► We report a prospective cohort of suspected and 
confirmed COVID-19 cases from a primary care ini-
tiative in the Brazilian municipality of São Caetano 
do Sul.
 ► By systematically testing consecutive suspected 
community cases with molecular and serological 
tests, we were able to address the diagnostic value 
of clinical features of mild- to- moderate COVID-19 in 
primary care.
 ► Prospective follow- up of confirmed cases and link-
age with hospital datasets allowed us to describe 
the natural history of a primary care COVID-19 
population.
 ► A limitation of the work was that not all PCR- negative 
participants underwent serology testing due to loss 
to follow- up.
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analysis coming from these primary care response systems 
can inform policy decisions.
PHC in Brazil is provided by the publicly funded Unified 
Health System (SUS—Portuguese acronym) within the 
family health strategy (Estratégia Saúde da Família). Provi-
sion of care is centred around a healthcare unit with a 
multiprofessional team that is responsible for all residents 
in the immediate catchment area.8 Nearly two- thirds of 
the Brazilian population is covered by the family health 
strategy.8
In Brazil, the first case of COVID-19 was identified in the 
city of São Paulo on 26 February 2020.9 As of 1 December 
2020, there were over 6 million confirmed cases nation-
ally, with São Paulo contributing a fifth of these.10 The 
reasons for the exceptionally large epidemic in Brazil 
have been discussed elsewhere.11–13 In March 2020, the 
Municipal Health Department of the municipality of 
São Caetano do Sul—part of the Greater Metropolitan 
Region of São Paulo—began to develop a clinical and 
testing platform to organise its COVID-19 response. The 
aim was to provide universal detection and management 
of symptomatic cases and their contacts. The platform 
was developed in partnership with two local universities—
the Municipal University of São Caetano do Sul (USCS) 
and the University of Sao Paulo—and called ‘Corona São 
Caetano’.
Large- scale community- based observational cohorts 
are difficult to establish under epidemic circumstances, 
particularly if the risk of exposure for research personnel 
is high. Hence, most COVID-19 epidemiological and clin-
ical studies have been hospital- based,14–16 and therefore 
tend to include more severe cases whose findings may not 
be generalisable to the general population,17 although 
some limited descriptions from ambulatory settings are 
available.18–20 The objectives of this study were to describe 
the epidemiological indicators of the early phase of the 
programme rollout; and to describe the clinical, virolog-
ical and natural history features (including hospitalisa-
tion and deaths) of SARS- CoV-2 infection among patients 
identified in primary care.
METHODS
Setting
The municipality of São Caetano do Sul has a population 
of 161 000 inhabitants.21 The city’s population is older 
than the Brazilian population21 and its Human Develop-
ment Index is one of the highest in the country. Nearly all 
(97.4%) children aged 6–14 years are in education and 
31% of the population have completed higher educa-
tion22 (Brazilian national average is 11%).
Corona São Caetano platform
The objective of the platform was to offer clinical care for 
patients with influenza syndrome and suspected COVID-
19. Through the multimedia platform (website or phone 
call), patients could be triaged and guided in relation to 
their clinical needs and tested, without having to leave 
their homes or go to health facilities, unless seriously ill. 
This strategy aimed at reducing the workload in health 
units and the risk of SARS- CoV-2 transmission in the 
population served by these health units. Patients’ general 
practitioners (GPs) were informed of lab results and had 
access to clinical data stored in the platform. GPs were 
expected to call patients being assisted by the platform 
and provide medical assistance through home visits or at 
the primary care clinic if needed. In general, the drugs 
prescribed through the platform were restricted to anal-
gesics and antipyretics. The platform was designed so that 
clinical information was collected in a standardised way 
for research purposes.
Residents of the municipality aged 12 years and older 
with suspected COVID-19 symptoms were encouraged, 
through local media reports, to contact the dedicated 
Corona São Caetano platform via the website or by phone. 
They were invited to complete an initial screening ques-
tionnaire that included sociodemographic data; informa-
tion on symptoms type, onset and duration; and recent 
contacts.
Patients meeting the suspected COVID-19 case defini-
tion (ie, having at least two of the following symptoms: 
fever, cough, sore throat, coryza or change in/loss of 
smell (anosmia); or one of these symptoms plus at least 
two other symptoms consistent with COVID-19) were 
further evaluated, while people not meeting these criteria 
were reassured, advised to stay at home and contact the 
service again if they were to develop new symptoms or 
worsening of current ones. The case definition was 
developed in consultation with infectious disease and 
primary care specialists to encompass the known symp-
toms of COVID-19 and is similar to the Brazilian national 
case definition.23 Patients were then called by a medical 
student to complete a risk assessment. All pregnant 
women, and patients meeting predefined triage criteria 
for severe disease (see online supplemental material 1), 
were advised to attend a hospital service—either an emer-
gency department or outpatient service, depending on 
availability. All other patients were offered a home visit 
for self- collection of a nasopharyngeal swab (NPS).
Sample collection
Patients self- collected NPS (both nostrils and throat) at 
their own homes under the supervision of trained health-
care personnel. We sent a link to an instructional video 
(https:// youtu. be/ rWZzV2ZP7KY) before the home visit 
to provide guidance on self- collection procedures. NPS 
for the molecular detection of SARS- CoV-2 has been 
recommended as an alternative method of collection 
for samples from patients with suspected COVID-19,24 as 
well as other respiratory diseases, and has the advantage 
of reducing the chance of aerosol transmission to health-
care professionals. Healthcare personnel were instructed 
to maintain a distance of 6 ft from the patient and to wear 
personal protective equipment at all times. Samples were 
immediately put on a cool box between 2°C–8°C and 
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stored at 4°C in a fridge until shipment to the lab within 
24 hours.
Follow-up procedures
Patients testing SARS- CoV-2 RT- PCR positive were 
followed up to 14 days25 (a maximum of seven phone 
calls) from completion of their initial questionnaire. 
They were contacted every 48 hours by a medical student 
who completed another risk assessment and recorded any 
ongoing or new symptoms. The purpose of the follow- up 
was to assess clinical evolution. Where patients were 
judged to be deteriorating or developing severe disease 
they were signposted to secondary care services. Patients 
testing RT- PCR negative were followed up by the PHC 
programme for their residential area. They were advised 
to contact the platform for a new consultation if they 
developed new symptoms. Starting on 19 May, when sero-
logical testing became available, RT- PCR- negative patients 
were recontacted to offer antibody (IgG/IgM combined) 
testing 14 days after their initial registration as long as 
they had become asymptomatic.
Study dates
The Corona São Caetano programme was launched on 6 
April 2020, with a 1 week pilot phase designed to test instru-
ments before roll- out. For this analysis, we included all 
patients making their first contact with the programme in 
its first month, that is, between 13 April and 13 May 2020. 
The period of follow- up (last date of data extraction) was 
4 June 2020, to account for the accrual period (3 weeks) 
of possible hospitalisations in the last included patients.
Laboratory methods
Due to shortages of some reagents, we used two RT- PCR 
platforms at different times during the study: ALTONA 
RealStar SARS- CoV-2 RT- PCR Kit 1.0 (Hamburg, 
Germany) and the Mico BioMed RT- qPCR kit (Seongnam, 
South Korea). For serology we tested 10 µL of serum or 
plasma (equivalent in performance) using a qualitative 
rapid chromatographic immunoassay (Wondfo Biotech, 
Guangzhou, China), which jointly detects anti- SARS- CoV-2 
IgG/IgM. The assay has been found to have a sensitivity 
of 81.5% and specificity of 99.1% in a US study.26 In our 
local validation, after 2 weeks of symptoms, the sensitivity 
in 59 RT- PCR confirmed cases was 94.9%, and specificity 
in 106 biobank samples from 2019 was 100%.
Statistical methods
We estimated the contribution of our platform to total 
number of COVID-19 cases diagnosed in São Caetano do 
Sul. To do this, we compared the number of cases diag-
nosed in our programme with official data released by 
the Municipal Department of Health in its daily bulletins 
(https:// coronavirus. saocaetanodosul. sp. gov. br).
Clinical and demographic data were extracted directly 
from the Corona São Caetano information system. To 
analyse clinical presentation, we first calculated the 
proportion and exact binomial 95% CIs of cases reporting 
each symptom in the three testing groups: SARS- CoV-2 
RT- PCR positive; RT- PCR negative/seropositive and 
RT- PCR negative/seronegative. We next combined 
RT- PCR and serology positive cases to make a confirmed 
COVID-19 group, and those negative on both tests to 
make a SARS- CoV-2- negative control group. We express 
the association between each symptom and a positive 
COVID-19 diagnosis as ORs and 95% CIs.
Next, we assessed associations between RT- PCR cycle 
thresholds (Cts) and other clinical features. ALTONA 
and MiCo BioMed RT- PCR kits each separately amplify 
two different SARS- CoV-2 viral genes, as such each 
patient had two Ct values. There was a high concordance 
between Cts for the two genes within each kit (online 
supplemental figure S1), and we opted therefore to use 
the mean of the two Ct values for each patient in all anal-
yses. We calculated univariable associations between Cts 
and age, sex, delay from symptom onset to NPS collection 
and presenting symptoms using simple linear regression. 
We then built a multivariable linear regression model 
to assess independent associations between presenting 
symptoms and RT- PCR Cts. As age, sex and time of swab 
collection may confound this relationship, we included 
these variables, as well as the RT- PCR platform (ALTONA 
vs MiCo BioMed), as covariates in the model.
For RT- PCR- positive patients, hospitalisations and 
deaths were extracted from the study platform. To extend 
the follow- up period and to capture RT- PCR- negative 
patients and those initially triaged to hospital (no study 
follow- up), hospitalisation and vital status was confirmed 
by linkage with two administrative databases: the munic-
ipal epidemiological surveillance dataset, as well as 
the state- wide influenza- like illness notification system 
(SIVEP- Gripe). Linkage was last performed on 5 June 
2020, 23 days after the last patient was enrolled, by the 
author SRPS who did not have access to the full analytic 
dataset. This author searched the SIVEP- Gripe system and 
the municipal epidemiological surveillance dataset using 
full name and date of birth. Categorical patient charac-
teristics were compared between patients requiring and 
those not requiring hospitalisation using a χ2 test or Fish-
er’s exact test. Continuous variables were compared using 
the Wilcoxon rank sum test. A multivariate analysis was 
not conducted due to the small number of individuals 
experiencing this outcome.
The cohort sample included consecutive cases 
presenting to the Corona São Caetano programme and 
a formal sample size calculation was not performed. 
Missing data were excluded. All analyses were conducted 
in R Software for Statistical Computing, V.3.6.3.27
Patient and public involvement
Patients were not involved in the planning of this research.
RESULTS
Epidemiological and programmatic indicators
Over the study period, there were 2073 presentations 
(49% phone call, 51% website), from 2011 individual 
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patients, that met the criteria for a suspected COVID-19 
case (see figure 1 for study flow). At initial phone inter-
view, 132 (6%) potential cases were advised to go directly 
to a health service based on the triage questions and 12 
(0.6%) because of pregnancy. Only four (3%) of referred 
patients were admitted to hospital and none died.
In total, 1583 individual patients were tested with 
RT- PCR for SARS- CoV-2; 444 (28.0%, 95% CI 25.9 to 
30.3) were positive. The proportion of positive results 
was stable over the study (online supplemental figure 
S2). Among the RT- PCR- negative group, 604 (53% of 
1136) underwent serology testing, of whom 52 (8.6%, 
95% CI 6.6 to 11.1) were seropositive. The median (IQR) 
time from symptom onset to serology collection was 31 
(26–37) days. The age- sex structure of patients being 
tested differed from the underlying population of São 
Caetano do Sul (online supplemental figure S3) with an 
over- representation of working- age adults and women. At 
the beginning of programme role out, 25% of notified 
COVID-19 cases in São Caetano do Sul were diagnosed in 
our programme. Over the study period, adherence to the 
programme increased, and by 13 May 2020, this figure 
had risen to 78%.
Of 444 RT- PCR- positive patients eligible for longitu-
dinal follow- up, 326 (73%) had their final follow- up 
visit at least 14 days after their initial presentation. Of 
the seven possible follow- up questionnaires, 384 (86%) 
patients with COVID-19 completed three or more, and 
162 (36%) completed all seven.
Participant characteristics
Patient characteristics are shown in table 1. Although 
women were over- represented in the cohort, there were 
proportionally more males in the RT- PCR- positive and 
seropositive groups compared with the seronegative 
group. Of note, 55% of RT- PCR- negative/seronegative 
patients had completed higher education compared with 
35% RT- PCR- positive patients (p<0.001, χ2 test). The 
median number of days from symptom onset to swab 
collection was 5.0 (IQR 4.0–7.0) among RT- PCR- positive 
patients and 6.0 (IQR 4.0–8.3) among RT- PCR- negative/
seropositive patients (p=0.06, Wilcoxon rank sum) 
(online supplemental figure S4). Chronic respiratory 
disease was less frequent in RT- PCR- positive than dual- 
negative patients.
Symptoms of COVID-19
The prevalence of individual symptoms at presentation is 
shown in figure 2A stratified by final diagnostic category. 
The most frequent symptoms among RT- PCR and sero-
positive patients were headache (82% and 75%), myalgia 
(80% and 80%), cough (77% and 63%) and fatigue 
(77% and 79%). Anosmia was present in 56% and 63% 
of RT- PCR- positive and seropositive patients, respectively, 
Figure 1 Patient flow chart for the Corona São Caetano platform between 13 April and 13 May 2020. In the upper section 
(white background), the numbers correspond to individual presentations to the system; among 2073 suspected cases, 60 had 
two presentations and 1 had three. In the lower section (grey background), numbers correspond to individual patients making 
up the final analytic groups.
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compared with 30% in those testing doubly negative. A 
similar pattern was observed for ageusia (53% and 53% 
vs 30%). Upper respiratory tract symptoms—including 
coryza, blocked nose, ageusia and anosmia—were more 
frequent in younger people (figure 2B). Symptoms were 
similar in men and women (figure 2C). The evolution of 
symptoms over time among RT- PCR- positive patients is 
shown in online supplemental figure S5.
The ORs for testing positive for SARS- CoV-2 (RT- PCR 
or serology) associated with each presenting symptom 
are shown in figure 3. The symptoms with strongest 
associations were anosmia (OR 3.3, 95% CI 2.6 to 4.4), 
fever (3.0, 95% CI 2.4 to 3.9) and ageusia (2.9, 95% CI 2.3 
to 3.8). The presence of sore throat (0.53, 95% CI 0.41 
to 0.68) and diarrhoea (0.72, 95% CI 0.55 to 0.96) were 
associated with a negative SARS- CoV-2 test.
Associations between SARS-CoV-2 RT-PCR cycle threshold 
(Ct) values, and demographic and clinical features
Figure 4 shows the associations between mean RT- PCR 
cycle threshold and demographic features and symp-
toms at presentation (the median (IQR) time from 
Table 1 Demographic and clinical characteristics of 1048 suspected COVID-19 cases undergoing diagnostic testing in the 





















Sex           
  Male 200 (45.0) 23 (44.2) 185 (33.5)     
  Female 244 (55.0) 29 (55.8) 367 (66.5) 1.0 <0.001
Age groups (years)           
  10–19 29 (6.5) 1 (1.9) 25 (4.5)     
  20–39 197 (44.4) 17 (32.7) 236 (42.8)     
  40–59 158 (35.6) 28 (53.8) 218 (39.5)     
  60+ 60 (13.5) 6 (11.5) 73 (13.2) 0.07 0.40
Educational level           
  Up to primary education 75 (16.9) 7 (13.5) 56 (10.2)     
  High school 214 (48.3) 19 (36.5) 194 (35.2)     
  University 154 (34.8) 26 (50.0) 301 (54.6) 0.10 <0.001
Essential occupation           
  Non- HCW essential job* 137 (30.9) 12 (23.1) 148 (26.9)     
  Carers 10 (2.3) 0 (0.0) 8 (1.5)     
  HCW 32 (7.2) 5 (9.6) 73 (13.2)     
  No 264 (59.6) 35 (67.3) 322 (58.4) 0.45 0.01
Body mass index (kg/m2)           
  <25 151 (34.2) 22 (42.3) 211 (38.4)     
  25–29 182 (41.2) 17 (32.7) 187 (34.0)     
  30–35 79 (17.9) 9 (17.3) 112 (20.4)     
  35+ 30 (6.8) 4 (7.7) 40 (7.3) 0.62 0.14
Comorbidities         
  Cardiovascular disease 88 (20.4) 9 (17.6) 129 (24.0) 0.89 0.40
  Diabetes mellitus 48 (11.1) 4 (7.8) 39 (7.3) 0.86 0.12
  Any chronic respiratory disease 37 (8.9) 9 (18.0) 79 (15.3) 0.13 0.01
  COPD 24 (5.5) 5 (9.8) 54 (10.1) 0.47 0.03
  Chronic kidney disease 1 (<1) 0 (0.0) 3 (1.0) 1.0 0.83
Time from symptom onset to swab 
collection (days), median (IQR)
  5.0 (4.0–7.0)   6.0 (4.0–8.3)   6.0 (4.0–9.0)   0.06   <0.001
Missing data—educational level 2; essential occupation 2; body mass index 4; cardiovascular disease 28; diabetes 31 mellitus; chronic respiratory 
disease 65; chronic kidney disease 27; COPD 28.
P values calculated by χ2 test, Fisher’s exact test or Wilcoxon rank sum test.
*Security, emergency services, supermarket, public transport and pharmacy workers.
COPD, chronic obstructive pulmonary disease; HCW, healthcare workers; RT, reverse transcriptase.
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presentation to swab was 1 (1–2) day). Older age was asso-
ciated with lower cycle thresholds, with a change in mean 
Ct of −0.05 (95% CI −0.09 to −0.01) for each additional 
year of age (figure 4B). The mean difference in Ct value 
was −1.36 (95% CI −2.49 to −0.23) in men compared with 
women (figure 4C). For each doubling in the number of 
days from symptom onset to swab collection the mean Ct 
value increased by 3.28 (95% CI 2.33 to 4.03) (figure 4A). 
Presenting symptoms of fever and arthralgia were associ-
ated with lower Cts, whereas anosmia, ageusia, vomiting, 
diarrhoea and nausea were associated with higher Cts 
(figure 4D and online supplemental table S1). After 
adjustment for age, sex, delay from symptom onset and 
RT- PCR platform used, fever (−0.06, 95% CI −2.11 to 
−0.001) and arthralgia (−1.24, 95% CI −2.18 to −0.10) 
remained associated with lower Cts, and anosmia (2.21, 
95% CI 1.0 to 3.29), ageusia (1.96, 95% CI 0.88 to 3.0) 
and diarrhoea (1.36, 95% CI 0.12 to 2.61) with higher Cts 
(online supplemental table S1).
Hospitalisations and deaths
Of the 444 RT- PCR- positive patients, 30 (6.8%) had been 
hospitalised by 5 June 2020, when the database linkage 
was last updated, and 3 (0.7%) had died; in- hospital 
mortality was therefore 10% (3/30). In 28 cases the 
date of admission was available. The median time from 
symptom onset to hospital admission was 7 (range 2–14) 
days. Among 1136 RT- PCR- negative patients, 6 (0.5%) 
had been admitted to hospital. One (<0.01% of 1,136) of 
these six patients died. None of the 604 RT- PCR- negative 
patients who underwent serology was admitted to hospital 
or died. Table 2 compares patient characteristics by hospi-
talisation status. Notably, hospitalised patients were older, 
Figure 2 Panel A presents prevalence (point) and exact binomial 95% CIs (vertical lines) of symptoms at presentation among 
patients with suspected COVID-19 according to reverse transcriptase (RT)- PCR result and serostatus (A). Panels B and C 
present the prevalence of presenting symptoms among patients with COVID-19 (RT- PCR and serology positive) stratified by age 
(B) and sex (C).
Figure 3 ORs (black dot) and 95% CIs (lines) for testing 
positive for COVID-19 (reverse transcriptase (RT)- PCR 
positive or serology positive) associated with the presence 
of each presenting symptom. Horizontal axis is on log 
scale. Point estimates of ORs are shown inline with their 
corresponding symptom.
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had more cardiovascular comorbidities and were more 
frequently obese.
DISCUSSION
We present a community- based cohort of suspected 
COVID-19 cases recruited through a primary care initiative 
in the Brazilian municipality of São Caetano do Sul. Offering 
RT- PCR testing to all patients presenting with symptoms 
compatible with COVID-19, the positivity rate was 28%, with 
8.6% of those testing negative subsequently found to be sero-
positive, that is, >35% of the cohort had a diagnosis of COVID-
19. Anosmia, ageusia and self- reported fever provided the 
greatest diagnostic value in identifying COVID-19. The rate 
of hospitalisation and deaths among RT- PCR- positive patients 
was low, at 6.8% and 0.7%, respectively. Our results provide 
important information on the clinical presentation, diag-
nostic testing and natural history of COVID-19 identified in 
the community.
The profile of suspected cases that tested positive for 
COVID-19 differed in some important respects from 
those testing negative. The lower educational level 
among positive cases suggests that, in São Caetano do 
Sul, the risk of exposure to COVID-19 follows a socio-
economic gradient, consistent with other findings from 
Brazil.13 28 Although more women presented to the plat-
form, proportionally more men tested positive, consistent 
with data from São Paulo showing a higher seropreva-
lence in men than women,11 and potentially reflecting 
different health- seeking behaviours. Comorbidities were 
mostly similar, although chronic respiratory disease was 
less frequent in those testing RT- PCR positive. This may 
be due to a proportion of presentations in those with 
chronic respiratory disease being explained by exacer-
bations of their underlying pathology from aetiologies 
other than SARS- CoV-2, as well as higher anxiety about 
COVID-19 in those with pre- existing respiratory disease.
Extrapolating the seropositivity rate among RT- PCR- 
negative patients to the 532 who were not tested with serology, 
we estimate that an additional 46 seropositive cases would 
have been identified. As such, 18% (98/542) of COVID-19 
cases were missed by RT- PCR in the setting of symptomatic 
presentations to primary care. This is similar to a pooled anal-
ysis showing a false- negative rate for RT- PCR of 20% at 3 days 
postsymptom onset.29 Viral load peaks around the time of 
symptom onset and remains high over the first symptomatic 
week (figure 4A).30 31 Consistent with this, we found a slightly 
longer delay to swab collection (due to delay in presenta-
tion to the platform) in RT- PCR false- negative patients than 
RT- PCR positive patients (online supplemental figure S4).
COVID-19 presents in a similar way to other respiratory 
viral illnesses. Indeed, in our cohort the most common symp-
toms of COVID-19—such as cough, fatigue, headache and so 
on—were reported with a similar frequency among patients 
testing negative. It is therefore important to have identified 
anosmia, ageusia, self- reported fever, myalgia and anorexia as 
the symptoms with greatest value in the differential diagnosis 
Figure 4 Relationship between mean reverse transcriptase (RT)- PCR cycle threshold (Ct) and day of illness course when the 
nasopharyngeal swab was collected (A), patient age (B), patient sex (C) and different symptoms at presentation (D). Panels 
A and B show the best- fit linear regression lines, panels C and D are violin plots (rotated kernel density plots showing the full 
distribution of data) of the Ct values with median (black dot) and IQR (black line).
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of COVID-19 in primary care. This is consistent with system-
atic review evidence highlighting anosmia and ageusia as key 
diagnostic features of COVID-19.32 It is of note that 30% of 
jointly RT- PCR and serology negative patients reported these 
symptoms, indicating that although indicative of COVID-19, 
the specificity of these symptoms is not high enough to rule in 
the diagnosis alone. Sore throat and diarrhoea—both consid-
ered symptoms of COVID-19 in other settings33—were more 
frequently due to other possible aetiologies in this primary 
care context.
These results are robust for a number of reasons. First, 
our sample is representative of the population of interest—
that is, consecutive patients with suspected COVID-19 in the 
community—instead of extrapolating from hospital cases. 
Symptom data were collected prospectively, eliminating 
recall or interviewer bias. Finally, we have a control group of 
patients who were negative for both RT- PCR and serology, 
minimising misclassification due to false- negative RT- PCR.
In our study, the proportion of patients with a positive 
SARS- CoV-2 RT- PCR requiring hospitalisation was low 
(7%). Early reports from China were of 13.8% of cases 
being severe,34 but this value was lower when under- 
ascertainment of cases was accounted for.35 36 This is 
because our cohort reflects mild- to- moderate cases, as 
severely ill patients are likely to have attended hospital 
directly. As such, only 3% of patients we triaged to attend 
health services were ultimately hospitalised, possibly due 
to self- selection of patients presenting to our service. 
Supporting this, our overall case fatality ratio among 
RT- PCR- positive patients was 0.7%. The rate of hospital-
isation was lower (0.5%) in those testing PCR- negative. 
These patients were admitted with a severe acute respi-
ratory syndrome of an aetiology other than SARS- CoV-2. 
The 14- fold higher admission rate among PCR- positive 
cases highlights the importance of molecular testing for 
SARS- CoV-2 in patients presenting with features of respi-
ratory viral illness to primary care.
As expected, the main determinant of Ct was the delay 
between symptom onset and swab collection, mostly due 
to the delay in reporting to the platform. After adjusting 
for this, as well as age and sex, we found that a self- reported 
fever and arthralgia were associated with lower Cts. The 
presence of these symptoms may identify patients with a 
higher viral load in the community. However, these results 
should be seen as purely exploratory, and the widespread 
Ct values around the regression line precludes a direct 
clinical application at present.
Our study has some limitations. First, the small sample size 
preluded a multivariate analysis of factors associated with 
hospitalisation or death. Next, serology was not performed on 
Table 2 Characteristics of RT- PCR- positive patients stratified by hospitalisation status
  
Hospitalised n=30
n (%) or median (IQR)
Not hospitalised n=414
n (%) or median (IQR) P value
Age (years)   
  10–19 1 (3) 28 (97)   
  20–39 6 (3) 191 (97)   
  40–59 14 (9) 144 (91)   
  60+ 9 (15) 51 (85) 0.006
Sex   
  Female 16 (7) 228 (93)   
  Male 14 (7) 186 (93) 0.852
Comorbidities   
  Cardiovascular disease 11 (13) 77 (87) 0.001
  Diabetes mellitus 8 (17) 40 (83) 0.007
  Any chronic respiratory disease 2 (5) 35 (95) 1.0
  COPD 1 (5) 23 (95) 1.0
  Chronic kidney disease 1 (100) 0 (0) 0.06
Body mass index (kg/m2)   
  <25 4 (3) 147 (97)   
  25–29 8 (4) 174 (96)   
  30–35 12 (15) 67 (85)   
  35+ 6 (20) 24 (80) <0.001
Time to presentation (days) 3 (3–4) 4 (3–5) 0.072
Missing data—body mass index 2; cardiovascular disease 12; diabetes mellitus 12; chronic respiratory disease 29; COPD 11; chronic kidney 
disease 12.
COPD, chronic obstructive pulmonary disease; RT, reverse transcriptase.
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all RT- PCR- negative patients due to ongoing symptoms, loss 
to follow- up or patient refusal. Of note, none of the RT- PCR- 
negative patients who were admitted to hospital underwent 
serology testing. This suggests that patients who were not 
tested with serology may have had a higher prevalence of 
COVID-19 than those that were tested. In addition, imperfect 
serology test performance (81% sensitivity)26 will introduced 
false- negative results. Taken together, these biases may have 
underestimated the true seroprevalence among RT- PCR- 
negative cases, as well as the false- negative rate of RT- PCR. 
The latter calculation may also have been influenced by the 
inclusion of RT- PCR- positive patients in the denominator, 
introducing an incorporation bias.37 Furthermore, the associ-
ation between symptoms and COVID-19 diagnosis was based 
on the comparison with doubly PCR and serology negative 
individuals. It is not clear how the exclusion of individuals 
that did not undergo serology testing would have influenced 
these associations. Finally, patients were not involved in the 
planning of the Corona platform or the research proposal.
A key strength to our study relates to the provision of 
PHC in Brazil and its symbiosis with medical training 
nationwide. PHC—within the family health strategy 
(Estratégia Saúde da Família)—is centred around a health-
care unit with a multiprofessional team that is responsible 
for all residents in the immediate catchment area.8 São 
Caetano do Sul has enough GP units within the family 
health strategy that all residents have access to primary 
care. Medical students from the municipal university 
(USCS) are integrated into the PHC teams and progres-
sively trained from the first year of medical school. Our 
initiative took advantage of this existing system, with the 
addition of an online platform allowing remote clinical 
assessment and follow- up. The suspension of normal clin-
ical training at the medical school provided the workforce. 
The partnership with the University of São Paulo, which 
provided the laboratory diagnostics, created the unique 
opportunity to establish our prospective community 
cohort of suspected and confirmed COVID-19 cases. But 
we believe that this infrastructure could be implemented 
in other regions with less resources. Other respiratory 
disease such as influenza, measles or tuberculosis may 
benefit from similar approach. However, further evalua-
tion of the impact of the Corona platform are required.
CONCLUSION
Systematic testing of all suspected COVID-19 cases was 
feasible within primary care services in a Brazilian munic-
ipality. Anosmia, agueusia and fever provide the greatest 
diagnostic discrimination from other similar primary care 
presentations. Home care is a valid approach for most of 
these patients with a low rate of hospitalisation and death.
Our programme model—integrating multimedia tech-
nology, telehealth with universal access to primary care—
may be successful in other contexts.
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